Arzerra ofatumumab regulatory update

The U.K.'s NICE issued guidance recommending against the use of Arzerra ofatumumab from GlaxoSmithKline and Genmab to treat chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab...